ProMetic Life Sciences Corporate Presentation 2016

ProMetic Life Sciences presents its 2016 corporate strategy focusing on advancing therapies addressing the healing process through small molecule drugs and plasma protein therapies. The presentation covers clinical progress on key programs including PBI-4050 for metabolic syndrome and Type 2 diabetes, plasminogen for orphan indications, and IVIG, alongside H2 2016 financial results and clinical milestones.